545. Transductionally-Retargeted Infectivity Selective Oncolytic Adenovirus With Redesigned AB-Loop Targeting Cell Surface Mesothelin

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)36349-3
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

506. Adenovirus Vectors Transductionally Retargeted to Her2/Neu for Prostate Tumour Treatment

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2010English

61PArming Oncolytic Adenovirus With FAP-targeting Bispecific T-Cell Engager to Improve Antitumor Efficacy

Annals of Oncology
MedicineOncologyHematology
2017English

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Cancer Therapy With a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors

Clinical Cancer Research
Cancer ResearchOncology
2004English

A Novel Oncolytic Adenovirus Targeting to Telomerase Activity in Tumor Cells With Potent

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Oncolytic Herpes Virus Retargeted to HER-2

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3

PLoS ONE
Multidisciplinary
2015English

Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted Against the Urokinase Receptor

Cancer Research
Cancer ResearchOncology
2009English

pH-sensitive Oncolytic Adenovirus Hybrid Targeting Acidic Tumor Microenvironment and Angiogenesis

Journal of Controlled Release
Pharmaceutical Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy